ROSIGLITAZONE 2 MG
ROSIGLITAZONE (ROSIGLITAZONE MALEATE) : 2 MG · DIN 02403366 · AA PHARMA INC
Health Canada status: MARKETED
What is ROSIGLITAZONE?
ROSIGLITAZONE 2 MG contains ROSIGLITAZONE (ROSIGLITAZONE MALEATE) : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02403366, held by AA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 17-Sep-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ROSIGLITAZONE used for?
Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus when other agents are inadequate or inappropriate. Requires written informed consent. (Max 200 chars)
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02403366 |
|---|---|
| Brand name | ROSIGLITAZONE |
| Generic / active ingredient | ROSIGLITAZONE (ROSIGLITAZONE MALEATE) : 2 MG |
| Manufacturer | AA PHARMA INC |
| Strength | 2 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A10BG02 ROSIGLITAZONE |
| AHFS class | 68:20.28 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Sep-2019 |
| Original market date | 2017-02-21 00:00:00 |
How is it administered?
Adjunct to diet/exercise. Only indicated with metformin OR a sulfonylurea in combination. Monitor liver enzymes before and during therapy. Discontinue if ALT > 3x ULN.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refers to Storage and Stability section).
How is it supplied?
Not explicitly detailed in provided text (refers to Dosage Forms, Composition and Packaging Section).
Contraindications
NYHA Class I-IV heart failure; hypersensitivity; serious hepatic impairment; pregnancy.
Warnings and precautions
Serious: Can cause/exacerbate congestive heart failure and fluid retention. Increased risk of cardiac ischemia. Increased risk of bone fractures. Potential for macular edema.
What can be used instead?
Other Canadian products sharing ATC code A10BG02 ROSIGLITAZONE. 3 of 21 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ROSIGLITAZONE | 4 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02403374 |
| ROSIGLITAZONE | 8 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02403382 |
| AVANDIA | 2 MG | TABLET | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02241112 |
| AVANDIA | 4 MG | TABLET | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02241113 |
| AVANDIA | 8 MG | TABLET | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02241114 |
| DOM-ROSIGLITAZONE | 2 MG | TABLET | DOMINION PHARMACAL | CANCELLED PRE MARKET | DIN 02307553 |
| DOM-ROSIGLITAZONE | 4 MG | TABLET | DOMINION PHARMACAL | CANCELLED PRE MARKET | DIN 02307561 |
| DOM-ROSIGLITAZONE | 8 MG | TABLET | DOMINION PHARMACAL | CANCELLED PRE MARKET | DIN 02307588 |
| MYLAN-ROSIGLITAZONE | 2 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED PRE MARKET | DIN 02354349 |
| MYLAN-ROSIGLITAZONE | 4 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED PRE MARKET | DIN 02354357 |
Who else supplies ROSIGLITAZONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ROSIGLITAZONE appears in 4 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.